Patients who remain in remission per the investigator following treatment with brentuximab vedotin. Includes patients who remain in remission according to the investigator, are still on study being followed for survival, and have not started new anticancer therapy (n = 18). Patients are shaded according to their best response on treatment with brentuximab vedotin. Six patients received an allogeneic stem cell transplant shortly after completing treatment with brentuximab vedotin. The 2 patients with a PR to brentuximab vedotin achieved a CR following transplant. Subsequent to end of treatment, 1 patient (indicated by an asterisk) received continued treatment with brentuximab vedotin as part of a separate treatment extension protocol.